''For several years a company initially called Advanced Magnetics (and later known as AMAG Pharma), with its partners, spent a good deal of money developing and seeking approval of a product called ferumoxtran-10. Ferumoxtran-10 was an imaging agent ...'
''One of the major issues in the management of prostate cancer is the identification of early physical (as opposed to biochemical) evidence of metastatic disease. For some years now, an imaging agent known as ferumoxtran-10 (Combidex) has been in ...'
Wednesday, 17 June 2009 by prostatecancerinfolink.net
•
News
top
